Jun. 10 at 11:11 PM
$CPIX legacy asset sale THEN we see the extended dmd results, fda ruling and schleroderma results. "IF" significant Parent of DMD patients are as active as they were with Sarepta's DMD drugs, then ifetroban has a shot at acclerated approval. At minimum we should hear that ifetroban is a phase 3 ready asset and that the FDA has identified a trial whose characteristics (patient #, endpoints etc.) are reasonable. In our view if we only have a phase 3 ready DMD asset, then the drug in that indication alone should have a present value of
$350 mm or more. Add cash and voucher to that, in a company sale, and you get
$500 mm or so. This assumes nothing worth pursuing in the other indications. Of course, we know the cancer metastatis results have some current present value. And Schleroderma would add to that if there are efficacy signals worth pursuing.
